Contrasting mechanisms of interferon-α inhibition by intravenous immunoglobulin after induction by immune complexes versus toll-like receptor agonists

Arthritis and Rheumatism

Volumn 65, Issue 10, 2013, Pages 2713-2723

  Wiedeman, Alice E ^a   Santer, Deanna M ^a   Yan, Wei ^b   Miescher, Sylvia ^c   Käsermann, Fabian ^c   Elkon, Keith B ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b AMGEN INC   (United States)

^c CSL Behring   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CYTOKINE; FC RECEPTOR IIA; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G; PROSTAGLANDIN E2; SIALIC ACID; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR AGONIST;

ANTIGEN ANTIBODY COMPLEX; ARTICLE; BINDING AFFINITY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; INTERFERON PRODUCTION; MONOCYTE; MONONUCLEAR CELL; PRIORITY JOURNAL; SIALYLATION; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANTIGEN-ANTIBODY COMPLEX; CELLS, CULTURED; DENDRITIC CELLS; DINOPROSTONE; HUMANS; IMMUNOGLOBULIN G; INJECTIONS, INTRAVENOUS; INTERFERON-ALPHA; LUPUS ERYTHEMATOSUS, SYSTEMIC; RECEPTORS, IGG; TOLL-LIKE RECEPTOR 7; TOLL-LIKE RECEPTOR 9; TOLL-LIKE RECEPTORS;

EID: 84885131046     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.38082     Document Type: Article

References (51)

1. Nimmerjahn F, Ravetch JV,. Anti-inflammatory actions of intravenous immunoglobulin. Annu Rev Immunol 2008; 26: 513-33.
2. Vaitla PM, McDermott EM,. The role of high-dose intravenous immunoglobulin in rheumatology. Rheumatology (Oxford) 2010; 49: 1040-8.
3. Ronnblom L,. The type I interferon system in the etiopathogenesis of autoimmune diseases. Ups J Med Sci 2011; 116: 227-37.
4. Lovgren T, Eloranta ML, Bave U, Alm GV, Ronnblom L,. Induction of interferon-α production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG. Arthritis Rheum 2004; 50: 1861-72.
5. Martin DA, Elkon KB,. Autoantibodies make a U-turn: the Toll hypothesis for autoantibody specificity. J Exp Med 2005; 202: 1465-9.
6. Santer DM, Yoshio T, Minota S, Moller T, Elkon KB,. Potent induction of IFN-α and chemokines by autoantibodies in the cerebrospinal fluid of patients with neuropsychiatric lupus. J Immunol 2009; 182: 1192-201.
7. Santer DM, Hall BE, George TC, Tangsombatvisit S, Liu CL, Arkwright PD, et al. C1q deficiency leads to the defective suppression of IFN-α in response to nucleoprotein containing immune complexes. J Immunol 2010; 185: 4738-49.
8. Santer DM, Wiedeman AE, Teal TH, Ghosh P, Elkon KB,. Plasmacytoid dendritic cells and C1q differentially regulate inflammatory gene induction by lupus immune complexes. J Immunol 2012; 188: 902-15.
9. Arnold JN, Wormald MR, Sim RB, Rudd PM, Dwek RA,. The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu Rev Immunol 2007; 25: 21-50.
10. Blank M, Shoenfeld Y,. Sialic acid-IVIg targeting CD22. Blood 2010; 116: 1630-2.
11. Leontyev D, Katsman Y, Ma XZ, Miescher S, Kasermann F, Branch DR,. Sialylation-independent mechanism involved in the amelioration of murine immune thrombocytopenia using intravenous gammaglobulin. Transfusion 2012; 52: 1799-805.
12. Schwab I, Biburger M, Kronke G, Schett G, Nimmerjahn F,. IVIg-mediated amelioration of ITP in mice is dependent on sialic acid and SIGNR1. Eur J Immunol 2012; 42: 826-30.
13. Schwab I, Seeling M, Biburger M, Aschermann S, Nitschke L, Nimmerjahn F,. B cells and CD22 are dispensable for the immediate antiinflammatory activity of intravenous immunoglobulins in vivo. Eur J Immunol 2012; 42: 3302-9.
14. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-7.
15. Kasermann F, Boerema DJ, Ruegsegger M, Hofmann A, Wymann S, Zuercher AW, et al. Analysis and functional consequences of increased Fab-sialylation of intravenous immunoglobulin (IVIG) after lectin fractionation. PLoS One 2012; 7: e37243.
16. Van Mirre E, Teeling JL, van der Meer JW, Bleeker WK, Hack CE,. Monomeric IgG in intravenous Ig preparations is a functional antagonist of FcγRII and FcγRIIIb. J Immunol 2004; 173: 332-9.
17. Aubin E, Lemieux R, Bazin R,. Indirect inhibition of in vivo and in vitro T-cell responses by intravenous immunoglobulins due to impaired antigen presentation. Blood 2009; 115: 1727-34.
18. Kurlander RJ, Batker J,. The binding of human immunoglobulin G1 monomer and small, covalently cross-linked polymers of immunoglobulin G1 to human peripheral blood monocytes and polymorphonuclear leukocytes. J Clin Invest 1982; 69: 1-8.
19. Pfueller SL, Weber S, Luscher EF,. Studies of the mechanism of the human platelet release reaction induced by immunologic stimuli. III. Relationship between the binding of soluble IgG aggregates to the Fc receptor and cell response in the presence and absence of plasma. J Immunol 1977; 118: 514-24.
20. Bave U, Magnusson M, Eloranta ML, Perers A, Alm GV, Ronnblom L,. FcγRIIa is expressed on natural IFN-α-producing cells (plasmacytoid dendritic cells) and is required for the IFN-α production induced by apoptotic cells combined with lupus IgG. J Immunol 2003; 171: 3296-302.
21. Su K, Yang H, Li X, Li X, Gibson AW, Cafardi JM, et al. Expression profile of FcγRIIb on leukocytes and its dysregulation in systemic lupus erythematosus. J Immunol 2007; 178: 3272-80.
22. Anthony RM, Wermeling F, Ravetch JV,. Novel roles for the IgG Fc glycan. Ann N Y Acad Sci 2012; 1253: 170-80.
23. Stadlmann J, Weber A, Pabst M, Anderle H, Kunert R, Ehrlich HJ, et al. A close look at human IgG sialylation and subclass distribution after lectin fractionation. Proteomics 2009; 9: 4143-53.
24. Zhu D, McCarthy H, Ottensmeier CH, Johnson P, Hamblin TJ, Stevenson FK,. Acquisition of potential N-glycosylation sites in the immunoglobulin variable region by somatic mutation is a distinctive feature of follicular lymphoma. Blood 2002; 99: 2562-8.
25. Ronnblom L, Eloranta ML, Alm GV,. The type I interferon system in systemic lupus erythematosus [review]. Arthritis Rheum 2006; 54: 408-20.
26. Vallin H, Perers A, Alm GV, Ronnblom L,. Anti-double-stranded DNA antibodies and immunostimulatory plasmid DNA in combination mimic the endogenous IFN-α inducer in systemic lupus erythematosus. J Immunol 1999; 163: 6306-13.
27. Payvandi F, Amrute S, Fitzgerald-Bocarsly P,. Exogenous and endogenous IL-10 regulate IFN-α production by peripheral blood mononuclear cells in response to viral stimulation. J Immunol 1998; 160: 5861-8.
28. Bave U, Vallin H, Alm GV, Ronnblom L,. Activation of natural interferon-α producing cells by apoptotic U937 cells combined with lupus IgG and its regulation by cytokines. J Autoimmun 2001; 17: 71-80.
29. Eloranta ML, Lovgren T, Finke D, Mathsson L, Ronnelid J, Kastner B, et al. Regulation of the interferon-α production induced by RNA-containing immune complexes in plasmacytoid dendritic cells. Arthritis Rheum 2009; 60: 2418-27.
30. 2 inhibits IFN-α secretion and Th1 costimulation by human plasmacytoid dendritic cells via E-prostanoid 2 and E-prostanoid 4 receptor engagement. J Immunol 2010; 184: 677-84.
31. 2 and transforming growth factor-β synergize to inhibit plasmacytoid dendritic cell-derived interferon-α. Immunology 2009; 128: 439-50.
32. Kessel A, Peri R, Haj T, Snir A, Slobodin G, Sabo E, et al. IVIg attenuates TLR-9 activation in B cells from SLE patients. J Clin Immunol 2011; 31: 30-8.
33. Nimmerjahn F, Ravetch JV,. The antiinflammatory activity of IgG: the intravenous IgG paradox. J Exp Med 2007; 204: 11-5.
34. Anthony RM, Wermeling F, Karlsson MC, Ravetch JV,. Identification of a receptor required for the anti-inflammatory activity of IVIG. Proc Natl Acad Sci U S A 2008; 105: 19571-8.
35. H2 pathway. Nature 2011; 475: 110-3.
36. Meyer-Wentrup F, Benitez-Ribas D, Tacken PJ, Punt CJ, Figdor CG, de Vries IJ, et al. Targeting DCIR on human plasmacytoid dendritic cells results in antigen presentation and inhibits IFN-α production. Blood 2008; 111: 4245-53.
37. Guhr T, Bloem J, Derksen NI, Wuhrer M, Koenderman AH, Aalberse RC, et al. Enrichment of sialylated IgG by lectin fractionation does not enhance the efficacy of immunoglobulin G in a murine model of immune thrombocytopenia. PLoS One 2011; 6: e21246.
38. Davies J, Jiang L, Pan LZ, LaBarre MJ, Anderson D, Reff M,. Expression of GnTIII in a recombinant anti-CD20 CHO production cell line: expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FCγRIII. Biotechnol Bioeng 2001; 74: 288-94.
39. Ferrara C, Grau S, Jager C, Sondermann P, Brunker P, Waldhauer I, et al. Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcγRIII and antibodies lacking core fucose. Proc Natl Acad Sci U S A 2011; 108: 12669-74.
40. Ferrara C, Stuart F, Sondermann P, Brunker P, Umana P,. The carbohydrate at FcγRIIIa Asn-162: an element required for high affinity binding to non-fucosylated IgG glycoforms. J Biol Chem 2006; 281: 5032-6.
41. Shields RL, Lai J, Keck R, O'Connell LY, Hong K, Meng YG, et al. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human FcγRIII and antibody-dependent cellular toxicity. J Biol Chem 2002; 277: 26733-40.
42. Scallon BJ, Tam SH, McCarthy SG, Cai AN, Raju TS,. Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality. Mol Immunol 2007; 44: 1524-34.
43. Tomana M, Schrohenloher RE, Koopman WJ, Alarcon GS, Paul WA,. Abnormal glycosylation of serum IgG from patients with chronic inflammatory diseases. Arthritis Rheum 1988; 31: 333-8.
44. Axford JS, Cunnane G, Fitzgerald O, Bland JM, Bresnihan B, Frears ER,. Rheumatic disease differentiation using immunoglobulin G sugar printing by high density electrophoresis. J Rheumatol 2003; 30: 2540-6.
45. Mimura Y, Ashton PR, Takahashi N, Harvey DJ, Jefferis R,. Contrasting glycosylation profiles between Fab and Fc of a human IgG protein studied by electrospray ionization mass spectrometry. J Immunol Methods 2007; 326: 116-26.
46. Wormald MR, Rudd PM, Harvey DJ, Chang SC, Scragg IG, Dwek RA,. Variations in oligosaccharide-protein interactions in immunoglobulin G determine the site-specific glycosylation profiles and modulate the dynamic motion of the Fc oligosaccharides. Biochemistry 1997; 36: 1370-80.
47. H residue of a monoclonal antibody against α(1→6) dextran increases its affinity for antigen. J Exp Med 1988; 168: 1099-109.
48. Wang J, Balog CI, Stavenhagen K, Koeleman CA, Scherer HU, Selman MH, et al. Fc-glycosylation of IgG1 is modulated by B-cell stimuli. Mol Cell Proteomics 2011; 10: M110.004655.
49. + monocytes, promote Th17 responses to Candida albicans. Eur J Immunol 2011; 41: 2915-24.
50. Cairns AP, Crockard AD, Bell AL,. The CD14+ CD16+ monocyte subset in rheumatoid arthritis and systemic lupus erythematosus. Rheumatol Int 2002; 21: 189-92.
51. 2 production of monocytes in systemic lupus erythematosus and rheumatoid arthritis. Diagn Immunol 1984; 2: 203-12.